VOYAGER THERAPEUTICS INC (VYGR)

Company Profile

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 125 full-time employees. The company went IPO on 2015-11-11. The firm focuses on leveraging its expertise in capsid discovery and neuropharmacology to address the delivery hurdles that have constrained the gene therapy and neurology disciplines. Its gene therapy platforms enable it to engineer, optimize, manufacture and deliver its adeno-associated virus (AAV)-based gene therapies. The company is identifying AAV capsids, the outer viral protein shells that enclose genetic material that makes up the vector payload. The company has developed an AAV capsid discovery platform called Tropism Redirection of AAV by Cell Type-Specific Expression of RNA (TRACERTM) that employs directed evolution to facilitate the selection of AAV capsids with enhanced tissue delivery characteristics, such as more effective delivery across the blood brain barrier (BBB). Its pipeline programs include superoxide dismutase 1 (SOD1), gene therapy for amyotrophic lateral sclerosis (ALS), and an anti-tau antibody for Alzheimer’s disease.

Company Info

VOYAGER THERAPEUTICS INC

64 Sidney Street

Cambridge MASSACHUSETTS 02139

P: 18572595340.0

CEO: G. Andre Turenne

Employees: 125

Website: https://www.voyagertherapeutics.com/